Lung cancer working group report
Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan....
Saved in:
Main Authors: | Nagahiro Saijo, Masahiro Fukuoka, Sumitra Thongprasert, Yukito Ichinose, Tetsuya Mitsudomi, Tony Shu Kam Mok, Yuichiro Ohe, Keunchil Park, Yi Long Wu |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50547 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Lung cancer working group report
by: Saijo N., et al.
Published: (2017) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018) -
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018) -
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)